Metagenomi (NASDAQ:MGX – Get Free Report) and Ernexa Therapeutics (NASDAQ:ERNA – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, risk, earnings and profitability.
Institutional & Insider Ownership
70.6% of Ernexa Therapeutics shares are owned by institutional investors. 12.5% of Metagenomi shares are owned by insiders. Comparatively, 0.5% of Ernexa Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Analyst Ratings
This is a summary of current ratings and recommmendations for Metagenomi and Ernexa Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Metagenomi | 1 | 0 | 2 | 0 | 2.33 |
| Ernexa Therapeutics | 1 | 1 | 1 | 0 | 2.00 |
Metagenomi presently has a consensus target price of $6.00, indicating a potential upside of 665.31%. Ernexa Therapeutics has a consensus target price of $30.00, indicating a potential upside of 1,335.41%. Given Ernexa Therapeutics’ higher possible upside, analysts clearly believe Ernexa Therapeutics is more favorable than Metagenomi.
Profitability
This table compares Metagenomi and Ernexa Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Metagenomi | -384.61% | -63.65% | -44.52% |
| Ernexa Therapeutics | N/A | -305.93% | -169.86% |
Risk & Volatility
Metagenomi has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500. Comparatively, Ernexa Therapeutics has a beta of 2.63, meaning that its share price is 163% more volatile than the S&P 500.
Valuation & Earnings
This table compares Metagenomi and Ernexa Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Metagenomi | $25.21 million | 1.17 | -$87.87 million | ($2.49) | -0.31 |
| Ernexa Therapeutics | $580,000.00 | 5.87 | -$14.08 million | ($14.35) | -0.15 |
Ernexa Therapeutics has lower revenue, but higher earnings than Metagenomi. Metagenomi is trading at a lower price-to-earnings ratio than Ernexa Therapeutics, indicating that it is currently the more affordable of the two stocks.
About Metagenomi
Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.
About Ernexa Therapeutics
Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Receive News & Ratings for Metagenomi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metagenomi and related companies with MarketBeat.com's FREE daily email newsletter.
